Edwards' percutaneous heart valve trial restarts
This article was originally published in Clinica
Executive Summary
Getting back on track with its US development programme for a heart valve that can be delivered percutaneously, Edwards Lifesciences has gained the all-clear to restart a feasibility trial of the product. In addition, an investigational tool that will enable the valve to be implanted through a mini-incision between the ribs, rather than through the patient's circulatory system, has proved successful in a human trial, the company has reported.